A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL.
作者信息
Best O G, Gardiner A C, Majid A, Walewska R, Austen B, Skowronska A, Ibbotson R, Stankovic T, Dyer M J S, Oscier D G
出版信息
Leukemia. 2008 Jul;22(7):1456-9. doi: 10.1038/sj.leu.2405092. Epub 2008 Jan 17.
PMID:18200038
Abstract
摘要
相似文献
1
A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL.一种使用依托泊苷加Nutlin-3a的新型功能检测方法可检测并区分慢性淋巴细胞白血病（CLL）中的ATM和TP53突变。
Leukemia. 2008 Jul;22(7):1456-9. doi: 10.1038/sj.leu.2405092. Epub 2008 Jan 17.
2
Functional analysis of the ATM-p53-p21 pathway in the LRF CLL4 trial: blockade at the level of p21 is associated with short response duration.LRF CLL4 试验中 ATM-p53-p21 通路的功能分析：p21 水平的阻断与短缓解持续时间相关。
Clin Cancer Res. 2012 Aug 1;18(15):4191-200. doi: 10.1158/1078-0432.CCR-11-2936. Epub 2012 Jun 6.
3
Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia.Mdm2抑制剂Nutlin-3a通过转录依赖性和转录非依赖性机制诱导p53介导的凋亡，并可能克服慢性淋巴细胞白血病中Atm介导的对氟达拉滨的耐药性。
Blood. 2006 Aug 1;108(3):993-1000. doi: 10.1182/blood-2005-12-5148. Epub 2006 Mar 16.
4
Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study.慢性淋巴细胞白血病患者中突变的共济失调毛细血管扩张症基因的变异对无进展生存期和总生存期无明显影响：一项癌症和白血病组 B 的研究。
Leuk Lymphoma. 2012 Sep;53(9):1743-8. doi: 10.3109/10428194.2012.668683. Epub 2012 Jun 2.
5
Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.英国白血病研究基金慢性淋巴细胞白血病 4 期临床试验中，双等位基因 ATM 失活显著降低了患者的生存率。
J Clin Oncol. 2012 Dec 20;30(36):4524-32. doi: 10.1200/JCO.2011.41.0852. Epub 2012 Oct 22.
6
[Gene atm and chronic lymphocytic leukemia - review].[共济失调毛细血管扩张症突变基因与慢性淋巴细胞白血病——综述]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Oct;16(5):1242-6.
7
New translocations in a case of atypical B-cell chronic lymphocytic leukemia: involvement of ATM, MLL, and TP53 genes.一例非典型B细胞慢性淋巴细胞白血病中的新易位：ATM、MLL和TP53基因受累
Cancer Genet Cytogenet. 2006 Sep;169(2):176-8. doi: 10.1016/j.cancergencyto.2006.02.021.
8
Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage.共济失调毛细血管扩张症突变缺陷型B细胞慢性淋巴细胞白血病发生于生发中心前细胞，导致损伤反应缺陷和染色体损伤未修复。
Blood. 2002 Jan 1;99(1):300-9. doi: 10.1182/blood.v99.1.300.
9
Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia.慢性淋巴细胞白血病中 ATM 异常的发生率及其临床意义。
Genes Chromosomes Cancer. 2012 Dec;51(12):1125-32. doi: 10.1002/gcc.21997. Epub 2012 Sep 6.
10
The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo.聚腺苷二磷酸核糖聚合酶抑制剂奥拉帕尼在体外和体内诱导 ATM 缺陷型淋巴肿瘤细胞的显著杀伤。
Blood. 2010 Nov 25;116(22):4578-87. doi: 10.1182/blood-2010-01-265769. Epub 2010 Aug 25.
引用本文的文献
1
The molecular map of CLL and Richter's syndrome.慢性淋巴细胞白血病和里希特综合征的分子图谱。
Semin Hematol. 2024 Apr;61(2):73-82. doi: 10.1053/j.seminhematol.2024.01.009. Epub 2024 Jan 23.
2
LCK facilitates DNA damage repair by stabilizing RAD51 and BRCA1 in the nucleus of chemoresistant ovarian cancer.LCK 在化疗耐药性卵巢癌的细胞核中稳定 RAD51 和 BRCA1 来促进 DNA 损伤修复。
J Ovarian Res. 2023 Jun 27;16(1):122. doi: 10.1186/s13048-023-01194-2.
3
The ClpP activator ONC-212 (TR-31) inhibits BCL2 and B-cell receptor signaling in CLL.ClpP激活剂ONC-212（TR-31）可抑制慢性淋巴细胞白血病（CLL）中的BCL2和B细胞受体信号传导。
EJHaem. 2021 Jan 14;2(1):81-93. doi: 10.1002/jha2.160. eCollection 2021 Feb.
4
IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironment.在模拟肿瘤微环境的体外条件下，IBL - 202与维奈托克在慢性淋巴细胞白血病中具有协同作用。
Blood Adv. 2020 Oct 27;4(20):5093-5106. doi: 10.1182/bloodadvances.2019001369.
5
ATM function and its relationship with ATM gene mutations in chronic lymphocytic leukemia with the recurrent deletion (11q22.3-23.2).具有复发性缺失（11q22.3 - 23.2）的慢性淋巴细胞白血病中ATM功能及其与ATM基因突变的关系
Blood Cancer J. 2016 Sep 2;6(9):e465. doi: 10.1038/bcj.2016.69.
6
Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification.通过多重连接依赖探针扩增评估慢性淋巴细胞白血病中p53和ATM的功能
Cell Death Dis. 2015 Aug 6;6(8):e1852. doi: 10.1038/cddis.2015.223.
7
ATM mutation rather than BIRC3 deletion and/or mutation predicts reduced survival in 11q-deleted chronic lymphocytic leukemia: data from the UK LRF CLL4 trial.ATM突变而非BIRC3缺失和/或突变预示着11号染色体缺失的慢性淋巴细胞白血病患者生存率降低：来自英国LRF CLL4试验的数据。
Haematologica. 2014 Apr;99(4):736-42. doi: 10.3324/haematol.2013.098574. Epub 2014 Feb 28.
8
Detection of TP53 dysfunction in chronic lymphocytic leukemia by an in vitro functional assay based on TP53 activation by the non-genotoxic drug Nutlin-3: a proposal for clinical application.基于非基因毒性药物Nutlin-3激活TP53的体外功能试验检测慢性淋巴细胞白血病中的TP53功能障碍：临床应用建议
J Hematol Oncol. 2013 Nov 5;6:83. doi: 10.1186/1756-8722-6-83.
9
Preparation of (-)-Nutlin-3 using enantioselective organocatalysis at decagram scale.使用对映选择性有机催化在十克规模制备(-)-Nutlin-3。
J Org Chem. 2013 Nov 1;78(21):10605-16. doi: 10.1021/jo401321a. Epub 2013 Oct 15.
10
Chronic lymphocytic leukemia-associated chromosomal abnormalities and miRNA deregulation.慢性淋巴细胞白血病相关的染色体异常与微小RNA失调
Appl Clin Genet. 2012 Mar 12;5:21-8. doi: 10.2147/TACG.S18669. Print 2012.
Zotero 插件